However, a subset of the patients develop resistance that is independent of the EGFR pathway, and multiple resistance mechanisms may co‐exist because of tumour heterogeneity (Sequist et al, 2015; Abbosh et al, 2017). The gene discussed is EGFR; the disease is neoplasm.